CellCarta

Spatial biology generates some of the richest data in translational research, but only when the analysis framework can keep up.

That's why we built our platform-agnostic mIF analysis framework, SPARTA: Spatial Phenotyping and Analysis in Regions of Tissue with AI.

Developed by our histopathology team, SPARTA is designed to standardize and accelerate how multiplex immunofluorescence datasets are processed, across imaging systems, across sites, and across programs, to ensure we generate interpretable, reproducible mIF data that can move biomarker programs forward with confidence.

Read the full CellTalk article by Yannick Waumans, our Executive Director of Histopathology Operations, and discover how SPARTA is changing how we turn spatial biology data into decisions.

🔗https://buff.ly/OQYhhTM

Over the past several months, we've been working hard to continue building the kind of partnerships that reflect what our sponsors need: fast turnarounds, broad reach, and flexible paths to CDx development to set your programs up for success.

Here's a quick look at recent major announcements:

🧬 Biofidelity: Expanding our multi-year strategic partnership, including exclusivity for Aspyre® Lung in clinical trial settings. Get actionable genomic alteration insights for NSCLC, with a fast turn around for critical patient management decisions.

🤖 Lunit Oncology: Launching a strategic partnership to accelerate AI-enabled digital pathology for translational research, clinical trials, and companion diagnostic programs.

🧬 Pillar Biosciences: A new multi-year global strategic partnership to expand rapid tumor profiling. Faster actionable genomic insights for complex clinical programs worldwide.

🏥 Sonic Healthcare USA: A partnership to bridge companion diagnostic development and commercial deployment. Sonic Healthcare USA becomes the first committed commercial laboratory partner in CellCarta's Lab Network, supporting our single-site PMA CDx bridging strategy across oncology, autoimmune disease, and other precision medicine programs.

🔬 Leica Biosystems: Expanding our proven companion diagnostic joint development model from China to biopharma sponsors worldwide, for a lower-risk, more streamlined path from early-stage assay to global CDx commercialization.

Our team is working hard to provide our sponsors coordinated, flexible support, for wherever your trials take you.

📰 Read all recent announcements: https://buff.ly/GSFqPzv

📩 Stay ahead by subscribing to our newsletter: https://buff.ly/7aaGWHQ

When you're looking for high parameter flow data for clinical trials, one option is spectral flow cytometry. With spectral flow, analysts can identify and quantify over 40 fluorochromes simultaneously for more detailed information about cell populations and biomarkers in a single sample.

At , make sure to find Xavier Dagenais-Lussier, Senior Scientist to learn how CellCarta scientists are accelerating assay design for clinical trials with flexible panel design.

The team will be at Booth #606 - book a meeting to make sure you catch them 👩‍🔬👨‍🔬 https://buff.ly/TqLZjT6

Press Release: CellCarta and Leica Biosystems are expanding their proven companion diagnostic (CDx) joint development model to biopharma sponsors worldwide.

Built on operational success in China, this partnership introduces a flexible, end-to-end CDx development framework that aligns assay development, clinical trial ex*****on, regulatory strategy, and commercial kit planning within a single coordinated model, while accommodating diverse regulatory pathways.

The result: a lower-risk, more streamlined path from early-stage assay to global CDx commercialization.

The partnership also leverages the integration of advanced digital pathology, combining Leica Biosystems' Aperio Scanners, IMS platform and expanding AI-enabled ecosystem with CellCarta's globally standardized digital pathology infrastructure for clinical trials.

Read the full announcement: https://buff.ly/iRwhnEL

CellCarta is attending ! The team is showing off CellEngine, our fast and flexible flow cytometry analysis software built to make your data analysis faster and more straightforward. Visit us at Booth 606!

Plus, look out for our poster: Accelerating spectral flow cytometry assay development for clinical trials with a flexible panel design.

Whether you're looking to analyze your existing data or a partner for clinical flow cytometry assay development, make sure to reach out: https://buff.ly/TqLZjT6

Big news: CellCarta and Sonic Healthcare USA are partnering to bridge companion diagnostic development and commercial deployment. We could not be more excited about what this means for our biopharma partners.

Bringing a companion diagnostic through regulatory approval is only half the journey. Getting that test into the hands of physicians and patients at scale has historically been one of the hardest problems in precision medicine.

This partnership is designed to solve that challenge.

Sonic Healthcare USA becomes the first committed commercial laboratory partner in CellCarta's Lab Network, supporting our single-site PMA CDx bridging strategy across oncology, autoimmune disease, and other precision medicine programs.

Learn more: https://buff.ly/T5ZM9i9